203 related articles for article (PubMed ID: 32844866)
1. A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
Kaundal B; Kushwaha AC; Srivastava AK; Karmakar S; Choudhury SR
J Mater Chem B; 2020 Sep; 8(37):8658-8670. PubMed ID: 32844866
[TBL] [Abstract][Full Text] [Related]
2. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Regulation of Bmi1 by Ubiquitination and Proteasomal Degradation Inhibit Bcl-2 in Acute Myeloid Leukemia.
Kushwaha AC; Mohanbhai SJ; Sardoiwala MN; Sood A; Karmakar S; Roy Choudhury S
ACS Appl Mater Interfaces; 2020 Jun; 12(23):25633-25644. PubMed ID: 32453568
[TBL] [Abstract][Full Text] [Related]
4. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S; Oellerich T; Agrawal-Singh S; Schenk T; Klein HU; Rohde C; Pabst C; Sauer T; Lerdrup M; Tavor S; Stölzel F; Herold S; Ehninger G; Köhler G; Pan KT; Urlaub H; Serve H; Dugas M; Spiekermann K; Vick B; Jeremias I; Berdel WE; Hansen K; Zelent A; Wickenhauser C; Müller LP; Thiede C; Müller-Tidow C
Nat Med; 2017 Jan; 23(1):69-78. PubMed ID: 27941792
[TBL] [Abstract][Full Text] [Related]
5. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
[TBL] [Abstract][Full Text] [Related]
6. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
8. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.
Li JM; Wang YY; Zhang W; Su H; Ji LN; Mao ZW
Int J Nanomedicine; 2013; 8():2101-17. PubMed ID: 23766646
[TBL] [Abstract][Full Text] [Related]
9. Delivery of EZH2-shRNA with mPEG-PEI nanoparticles for the treatment of prostate cancer in vitro.
Wu Y; Yu J; Liu Y; Yuan L; Yan H; Jing J; Xu G
Int J Mol Med; 2014 Jun; 33(6):1563-9. PubMed ID: 24714818
[TBL] [Abstract][Full Text] [Related]
10. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.
Li Q; Song W; Wang J
Biomed Pharmacother; 2019 Jan; 109():1793-1801. PubMed ID: 30551433
[TBL] [Abstract][Full Text] [Related]
11. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia.
Wang J; He N; Wang R; Tian T; Han F; Zhong C; Zhang C; Hua M; Ji C; Ma D
Sci Rep; 2020 Feb; 10(1):2706. PubMed ID: 32066746
[TBL] [Abstract][Full Text] [Related]
12. siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy.
Xia Y; Guo M; Xu T; Li Y; Wang C; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():1539-1552. PubMed ID: 29588583
[TBL] [Abstract][Full Text] [Related]
13. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
14. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299
[TBL] [Abstract][Full Text] [Related]
15. Silica nanoparticles and polyethyleneimine (PEI)-mediated functionalization: a new method of PEI covalent attachment for siRNA delivery applications.
Buchman YK; Lellouche E; Zigdon S; Bechor M; Michaeli S; Lellouche JP
Bioconjug Chem; 2013 Dec; 24(12):2076-87. PubMed ID: 24180511
[TBL] [Abstract][Full Text] [Related]
16. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract][Full Text] [Related]
19. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Sandow JJ; Infusini G; Holik AZ; Brumatti G; Averink TV; Ekert PG; Webb AI
Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28447382
[TBL] [Abstract][Full Text] [Related]
20. Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA.
Cho WY; Hong SH; Singh B; Islam MA; Lee S; Lee AY; Gankhuyag N; Kim JE; Yu KN; Kim KH; Park YC; Cho CS; Cho MH
Eur J Pharm Biopharm; 2015 Aug; 94():450-62. PubMed ID: 26141346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
